Welcome to our dedicated page for Charles Riv Labs Intl SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Charles River Laboratories International, Inc. filings document the company’s operating results, material events, governance matters, and capital-structure disclosures as a New York Stock Exchange-listed issuer with common stock trading under CRL. Form 8-K reports cover quarterly and annual financial results, guidance, share repurchase activity, completed portfolio changes, conference disclosures, and executive appointment and compensation matters.
Proxy materials describe shareholder voting matters, board elections, executive compensation, equity incentive plans, and auditor ratification. The filing record also reflects disclosure categories tied to the company’s drug discovery and development services, including segment performance for Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions, along with forward-looking risk language and compliance matters.
Charles River Laboratories director James C. Foster reported exempt, bona fide gifts and related trust transfers of 366,722 shares of common stock dated 2026-06-05. The Form 4 shows these shares moving among his direct holdings, revocable trusts he controls, and trusts associated with his spouse, all at a stated price of $0.00 per share, indicating no sale proceeds. Following these transactions, Foster holds 126,596 shares directly and 155,611 shares indirectly through a trust, plus additional indirect positions of 20,000 shares in a 2026 GRAT, 10,780 shares in a 2025 GRAT, 5,423 shares in a 2024 GRAT, and 10,000 shares in a trust held by his spouse.
Charles River Laboratories' CEO Birgit Girshick reported exempt insider transfers primarily structured as gifts rather than market sales. She made bona fide gifts totaling 6,772 shares of Common Stock on June 5, 2026, including a transfer of 3,386 shares to a revocable trust she controls under Rule 16a-13.
Following these transfers, she holds 36,013 Common shares directly and 43,803 shares indirectly through the revocable trust. She also holds stock options covering 8,722 shares of Common Stock, exercisable at $208.44 per share and expiring on May 31, 2034. These transactions did not involve any sale proceeds.
Charles River Laboratories executive Shannon M. Parisotto, Chief Executive Vice President for Discovery & Safety Assessment, reported non-market movements in Common Stock. On June 5, 2026, she made bona fide gifts totaling 3,058 shares, with 1,529 shares transferred as an exempt move under Rule 16a-13 to a revocable trust she controls.
After these transactions, she holds 9,853 Common Stock shares directly, 9,680 shares indirectly through a trust, and 28,510 shares indirectly via Karpathos Investments LLC. All reported actions are gifts or internal reallocations, not open-market purchases or sales.
Barg Steven reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories director Steven Barg received an equity grant as part of his board compensation. He was awarded 422 shares of Common Stock in the form of restricted stock units at a reference price of $174.79 per share, bringing his direct holdings to 3,287 shares following the grant.
The grant was made in lieu of director service fees for the term beginning on May 5, 2026. These restricted stock units will vest on the earlier of June 2, 2027 or the business day before the company’s next annual meeting of shareholders, making this a routine, compensation-related, non-market transaction.
Coleman Glenn reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories International EVP & CFO Glenn Coleman received a stock grant. On May 29, he was awarded 6,640 shares of common stock at a reference value of $180.71 per share as compensation, increasing his directly held stake to 27,752 shares.
A footnote explains that the unvested restricted stock units underlying this award will vest in equal annual installments on May 29, 2027, May 29, 2028, May 29, 2029, and May 29, 2030, subject to the applicable award terms.
Charles River Laboratories International EVP and Chief Information Officer Mark Mintz received an equity award of 2,534 shares of common stock at a reference price of $180.71 per share. To cover tax obligations, 305 shares on May 30, 2026 and 64 shares on May 31, 2026 were withheld as tax-withholding dispositions, not open-market sales. After these transactions, he directly held 9,546 shares. The related restricted stock units are scheduled to vest annually on May 29 of 2027, 2028, 2029, and 2030.
Charles River Laboratories executive Joseph W. LaPlume reported equity compensation activity involving company common stock. On May 29, he received a grant of 5,257 shares of Common Stock, increasing his direct holdings. The filing shows this as a grant or award, not an open-market purchase.
On May 30 and May 31, a total of 979 shares were disposed of at $180.71 per share to satisfy tax withholding obligations related to the award. These tax-withholding dispositions are not open-market sales. After these transactions, LaPlume directly holds 31,298 shares of Common Stock.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. executive Michael Gunnar Knell, SVP Finance and CAO, reported compensation-related equity activity in company common stock. On May 29, 2026, he received a grant of 1,837 shares of common stock valued at $180.71 per share as a stock award. On May 30, 2026 and May 31, 2026, a total of 200 shares (152 and 48 shares, respectively) were disposed of as tax-withholding transactions at the same reference price of $180.71 per share, meaning the shares were used to cover tax obligations rather than sold in the open market. After these transactions, Knell directly owned 16,152 shares of common stock. A footnote states that unvested restricted stock units will ratably vest each year on May 29, 2027, May 29, 2028, May 29, 2029, and May 29, 2030, indicating a multi-year vesting schedule for his equity awards.
Charles River Laboratories International Chief Executive Officer Birgit Girshick reported equity compensation and related tax withholding transactions. On May 29, 2026, she received a grant of 9,961 shares of common stock at $180.71 per share. On May 30–31, 2026, a total of 1,582 shares were disposed of as tax-withholding transactions at the same price. After these transactions, she directly owned 39,399 shares and indirectly held 40,417 shares through a revocable trust. A footnote states that unvested restricted stock units vest annually on May 29, 2027, 2028, 2029, and 2030.
Charles River Laboratories International director James C. Foster reported a set of equity holdings and one tax-related share disposition in company common stock. The filing shows 1,596 shares of common stock were disposed of at $180.71 per share as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold in the open market.
After this transaction, Foster directly holds 279,957 shares of common stock. The filing also lists several indirect holdings, including shares held by a spouse, by trusts, and by 2024 and 2025 GRAT vehicles. Overall, the activity appears routine and primarily administrative, focused on updating ownership records and satisfying tax requirements tied to equity compensation.